Biologics have rapidly established themselves as #8216;the next big thing#8217;, in the search for blockbuster wonder drugs, and everyone wants in, period. The relative sparseness of viable target companies has pushed the premiums to new highs, as the major global players compete to buy a future stake in the biologics arena. The latest addition to the list of companies to bow to shareholder pressure is MedImmune, which has agreed to be acquired by global giant AstraZeneca for US$15.6 B. This article explores the rationale behind the deal in order to provide an insight into why AstraZeneca was willing to go the extra mile for MedImmune.